Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | MC4R | P32245 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31547211 | 0.78 | SIGMAR1 (0.58) | SIGMAR1POLBCHRM1MC4RCHRM2 | |
| SCHEMBL13041010 | 0.78 | SIGMAR1 (0.58) | SIGMAR1POLBCHRM1MC4RCHRM2 | |
| SCHEMBL8386424 | 0.78 | MEN1 (0.47) | POLBCYP2D6MAPTHPGDMAPK1 | |
| SCHEMBL1177108 | 0.78 | ALDH1A1 (0.43) | CYP2D6KCNH2MAPTHPGDSMN1; SMN2 | |
| SCHEMBL6546455 | 0.77 | HRH4 (0.43) | MC4RHTR2AHTR2CMAPTMAPK1 | |
| SCHEMBL947117 | 0.76 | HPGD (0.46) | CYP2D6KCNH2MAPTHPGDSMN1; SMN2 | |
| SCHEMBL948363 | 0.73 | LMNA (0.50) | SIGMAR1POLBMAPTHPGDMAPK1 | |
| SCHEMBL949805 | 0.73 | SIGMAR1 (0.50) | SIGMAR1POLBHTR2ASLC6A3HPGD | |
| SCHEMBL1852773 | 0.71 | SIGMAR1 (0.39) | SIGMAR1POLBCHRM1MC4RHRH1 | |
| SCHEMBL2457519 | 0.71 | KDM1A (0.39) | CHRM1CHRM2CYP2D6CHRM3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107298686-B | A kind of psoralen amine derivant and purposes | 中国科学院新疆理化技术研究所 | 2018-10-26 | — | — | CN | claimed |
| CN-107298686-A | A kind of psoralen amine derivant and purposes | 中国科学院新疆理化技术研究所 | 2017-10-27 | — | — | CN | claimed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | claimed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | claimed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | claimed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | claimed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | claimed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| CN-107298686-B | A kind of psoralen amine derivant and purposes | 中国科学院新疆理化技术研究所 | 2018-10-26 | — | — | CN | disclosed |
| CN-107298686-A | A kind of psoralen amine derivant and purposes | 中国科学院新疆理化技术研究所 | 2017-10-27 | — | — | CN | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| EP-0288519-A4 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | — | 1992-04-15 | — | — | EP | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | SIGMAR1 862/4885POLB 1470/4885CHRM1 876/4885 |
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | SIGMAR1 647/4885POLB 1929/4885CHRM1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.